Title |
Safety and effectiveness of adalimumab in a clinical setting that reflects Canadian standard of care for the treatment of rheumatoid arthritis (RA): Results from the CanACT study
|
---|---|
Published in |
BMC Musculoskeletal Disorders, November 2011
|
DOI | 10.1186/1471-2474-12-261 |
Pubmed ID | |
Authors |
Boulos Haraoui, Alfred Cividino, Jacqueline Stewart, Benoît Guérette, Edward C Keystone |
Abstract |
This multicenter, open-label, prospective, single cohort study evaluated the effectiveness and safety of adalimumab in a clinical setting reflecting the Canadian standard of care for the treatment of patients with rheumatoid arthritis (RA). |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 77 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 1 | 1% |
Colombia | 1 | 1% |
Unknown | 75 | 97% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 9 | 12% |
Student > Master | 9 | 12% |
Researcher | 8 | 10% |
Other | 7 | 9% |
Student > Postgraduate | 6 | 8% |
Other | 19 | 25% |
Unknown | 19 | 25% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 31 | 40% |
Pharmacology, Toxicology and Pharmaceutical Science | 6 | 8% |
Unspecified | 3 | 4% |
Immunology and Microbiology | 3 | 4% |
Agricultural and Biological Sciences | 3 | 4% |
Other | 10 | 13% |
Unknown | 21 | 27% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 November 2011.
All research outputs
#15,238,442
of 22,656,971 outputs
Outputs from BMC Musculoskeletal Disorders
#2,440
of 4,024 outputs
Outputs of similar age
#161,874
of 238,843 outputs
Outputs of similar age from BMC Musculoskeletal Disorders
#53
of 65 outputs
Altmetric has tracked 22,656,971 research outputs across all sources so far. This one is in the 22nd percentile – i.e., 22% of other outputs scored the same or lower than it.
So far Altmetric has tracked 4,024 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.0. This one is in the 28th percentile – i.e., 28% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 238,843 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 20th percentile – i.e., 20% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 65 others from the same source and published within six weeks on either side of this one. This one is in the 9th percentile – i.e., 9% of its contemporaries scored the same or lower than it.